Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc.（AVIR）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
avir · 股价预测 · 4 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 4 位华尔街分析师
Hold
4 位分析师
共识
评级分布
12 个月目标价
High
$10.00
Consensus
$10.00
+130.9% upside
Low
$10.00
Median: $10 · Last Close: $4.33
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $4.23 | ↓ 2.36% |
1-day model range: $4.15–$4.31. Peak: $4.31 (-2.36%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | +6.5% |
| 2028 | — | +10.3% |
| 2029 | — | +12.4% |
| 2030 | — | +13.6% |
| 2031 | — | +14.3% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · AVIR · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-09 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2025-04-11 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2024-08-13 | Morgan Stanley | Upgrade ↑ | Underweight→Equal Weight |
| 2023-08-10 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
| 2023-03-16 | JP Morgan | Maintains | Neutral→Neutral |
| 2023-01-27 | SVB Leerink | Maintains | Market Perform→Market Perform |
| 2023-01-24 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2022-08-15 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2022-03-02 | JP Morgan | Maintains | Neutral→Neutral |
| 2022-03-01 | SVB Leerink | Maintains | Market Perform→Market Perform |
Wall Street analysts have recently issued updated ratings on Atea Pharmaceuticals, Inc. (AVIR) stock. Of the recent 23 rating actions, 1 were upgrades and 5 were downgrades. 4 analysts currently cover AVIR.
分析师推荐趋势
AVIR analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$68M
↑ 1089.5% YoY
Revenue Next Year
$7M
↓ 89.6% YoY
EPS This Year
$-1.80
EPS Next Year
$-1.73
↓ 4.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast AVIR EPS of $-1.80 for the current fiscal year, based on estimates from 3 analysts. The AVIR revenue forecast is $68M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
AVIR 股价预测由两类独立数据源支撑：来自 4 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。AVIR 的共识目标价为 $10.00（+130.9% 上行空间），分析师共识为 Hold。
AVIR 的短期预测（明日）为 $4.23（-2.36%）。 AVIR 对 2030 年的预测区间为 $5–$5。
Atea Pharmaceuticals, Inc. 在 NASDAQ 上市，代码 AVIR。AVIR 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 25% 对应 Hold 共识。
常见问题
AVIR 预测 · 8 个问题根据 4 位华尔街分析师，AVIR 的 12 个月平均目标价为 $10.00，最高 $10.00、最低 $10.00。若有图表，中位目标价可在上方查看。相对当前价 $4.33，隐含约 +130.9% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.